Proactive Investors - Run By Investors For Investors

Orgenesis to invest at least another US$1mln into Hemogenyx as part of latest collaboration deal

This time around, the investment is centred on Hemogenyx’s Hu-PHEC technology - a cell replacement product candidate that is being developed to generate cancer-free, patient-matched blood stem cells after transplantation into the patient
stem cell
Orgenesis could invest up to US$4mln in Hemogenyx over the next three years

Orgenesis is to invest at least another US$1mln into HemoGenyx Pharmaceuticals PLC (LON:HEMO) after the biopharma entered into a second collaboration deal in as many days.

Friday’s deal related to Hemogenyx’s advanced hematopoietic chimeras (AHC) – a new type of humanised mouse with a functional human immune system.

READ: Hemogenyx to receive US$1mln investment from Orgenesis

This latest agreement centres on Hemogenyx’s Human Postnatal Hemogenic Endothelial Cell (Hu-PHEC) technology.

Hu-PHEC is a cell replacement product candidate that is being developed to generate cancer-free, patient-matched blood stem cells after transplantation into the patient.

“We are very pleased to announce this further collaboration with Orgenesis to rapidly develop and bring to the market our Hu-PHEC technology,” said chief executive and co-found Vladislav Sandler.

“The collaboration is a testament to the value of our Hu-PHEC based approach to drastically improving bone marrow transplants.”

Up to US$4mln over three years

As with Friday’s agreement, Orgenesis, possibly alongside other investors, will invest at least another US$1mln in Hemogenyx through a convertible loan, which can be converted into either Hemogenyx or Orgenesis stock.

Orgenesis will also have the option to invest up to a further US$1mln in Hemogenyx over the next three years. Overall, Orgenesis could invest up to US$4mln in Hemogenyx over the next three years.

In addition, the Nasdaq company has been granted a non-exclusive licence to use, market and sell Hemogenyx’s technology, patents and products.

Hemogenyx, which will still manufacture the products and supply them to Orgenesis, will take a 12% cut of any profits Orgenesis makes from selling its technology.

In a separate manufacturing and supply agreement to be inked at a later date, Orgenesis will be able to exclusively supply Hemogenyx products at the end of the clinical development stage.

Should the two fail to sign such an agreement, Hemogenyx will pay Orgenesis an amount equal to 4% of gross revenue derived from the sale of the respective Hemogenyx Products.

Third collaboration agreement of October

In a note to clients, analysts at joint ‘house’ broker Northland Capital commented: “The agreement provides capital to further the development of the Hu-PHEC cell therapy product and has the potential to provide future revenue from royalties.”

They added: “This is the third collaboration agreement announced in October, following collaboration agreements with Janssen, a pharma company owned by Johnson & Johnson and Orgenesis regarding Hemogenyx’s AHC mouse model.

“This demonstrates the Company’s ability to generate investment from industry across its portfolio of products, an impressive feat for a preclinical stage company.“

In mid-afternoon trading, Hemogenyx shares were 1.7% lower at 2.90p, having gained over 9% in the past month.

 -- Adds analyst comment, share price --

View full HEMO profile View Profile

HemoGenyx Pharmaceuticals Timeline

Related Articles

blood
January 29 2019
"With multiple collaboration agreements and investment from industry we view the company as undervalued," says Northland

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use